The cellular RNA-binding protein EAP recognizes a conserved stem-loop in the Epstein-Barr virus small RNA EBER 1.

Mol Cell Biol

Department of Molecular Biophysics and Biochemistry, Howard Hughes Medical Institute, Yale University, New Haven, Connecticut 06536-0812.

Published: January 1993

EAP (EBER-associated protein) is an abundant, 15-kDa cellular RNA-binding protein which associates with certain herpesvirus small RNAs. We have raised polyclonal anti-EAP antibodies against a glutathione S-transferase-EAP fusion protein. Analysis of the RNA precipitated by these antibodies from Epstein-Barr virus (EBV)- or herpesvirus papio (HVP)-infected cells shows that > 95% of EBER 1 (EBV-encoded RNA 1) and the majority of HVP 1 (an HVP small RNA homologous to EBER 1) are associated with EAP. RNase protection experiments performed on native EBER 1 particles with affinity-purified anti-EAP antibodies demonstrate that EAP binds a stem-loop structure (stem-loop 3) of EBER 1. Since bacterially expressed glutathione S-transferase-EAP fusion protein binds EBER 1, we conclude that EAP binding is independent of any other cellular or viral protein. Detailed mutational analyses of stem-loop 3 suggest that EAP recognizes the majority of the nucleotides in this hairpin, interacting with both single-stranded and double-stranded regions in a sequence-specific manner. Binding studies utilizing EBER 1 deletion mutants suggest that there may also be a second, weaker EAP-binding site on stem-loop 4 of EBER 1. These data and the fact that stem-loop 3 represents the most highly conserved region between EBER 1 and HVP 1 suggest that EAP binding is a critical aspect of EBER 1 and HVP 1 function.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC358948PMC
http://dx.doi.org/10.1128/mcb.13.1.703-710.1993DOI Listing

Publication Analysis

Top Keywords

eber
10
cellular rna-binding
8
rna-binding protein
8
eap recognizes
8
epstein-barr virus
8
small rna
8
anti-eap antibodies
8
glutathione s-transferase-eap
8
s-transferase-eap fusion
8
fusion protein
8

Similar Publications

Gastric carcinoma with lymphoid stroma (GCLS) is characterized by dense intra-and peritumoral lymphocytic infiltration and a high rate of Epstein Barr Virus (EBV) infection, suggesting being a promising candidate for immunotherapy. We investigated correlations between PD-L1 expression and clinicopathologic factors, including EBV positivity and microsatellite instability (MSI) status in GCLSs. The study included resected 214 GCLSs and 300 gastric adenocarcinomas (GACs) for control.

View Article and Find Full Text PDF

Background: Activated Phosphoinositide 3-Kinase (PI3K) δ Syndrome (APDS), an inborn error of immunity due to upregulation of the PI3K pathway, leads to recurrent infections and immune dysregulation (lymphoproliferation and autoimmunity).

Methods: Clinical and genetic data of 28 APDS patients from 25 unrelated families were collected from fifteen Italian centers.

Results: Patients were genetically confirmed with APDS-1 (n = 20) or APDS-2 (n = 8), with pathogenic mutations in the PIK3CD or PIK3R1 genes.

View Article and Find Full Text PDF

The main objectives of the present study were to determine the effects of presynchronizing with a 1.0 g intravaginal progesterone device (IVPD) and prostaglandin F2α and to assess the effects of re-utilization of IVPD in a 2x2 factorial design, on the ovulatory response to first GnRH, ovarian status at different protocol stages, estrus expression and fertility in beef heifers submitted to a 5d-CO-Synch + Progesterone (P4) protocol. Beef heifers (n = 564) were assigned to 1 of 2 treatments at D-15: Pres5 (n = 283), where heifers received a (IVPD) for 5 days and administration of prostaglandin F2α (25 mg of dinoprost) at D-10; and Control (n = 281), where heifers received no treatment.

View Article and Find Full Text PDF
Article Synopsis
  • This study investigates the presence of therapeutic target molecules in esophagogastric junction (EGJ) and Barrett's adenocarcinomas, focusing on 114 non-Barrett's and 30 Barrett's cases.
  • Various molecular markers were assessed, revealing that a majority of EGJ (81.6%) and Barrett's (86.7%) adenocarcinomas expressed at least one target molecule, with PD-L1 having a significant correlation with better survival rates.
  • The findings suggest that most patients with EGJ and Barrett's adenocarcinoma could benefit from molecular targeted therapy, highlighting the importance of tailored treatments based on individual molecular profiles for improved outcomes.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!